Skip to main content
Advertising

Originally published April 28, 2014 at 7:27 AM | Page modified April 28, 2014 at 9:03 AM

  • Share:
           
  • Comments (0)
  • Print

Forest Labs to buy Furiex in deal worth $1.5B

A $25 billion bid to buy Forest Laboratories hasn't stopped the drugmaker from continuing to shop for deals of its own.


advertising

A $25 billion bid to buy Forest Laboratories hasn't stopped the drugmaker from continuing to shop for deals of its own.

Forest said Monday that it will spend as much as $1.5 billion to buy Furiex Pharmaceuticals Inc. in a deal that will give it one of the broadest product lines for gastrointestinal disease treatments.

Shares of Morrisville, N.C.-based Furiex soared in trading after the companies announced the deal.

Forest's latest acquisition bid comes more than two months after Ireland-based Actavis PLC said that it planned to buy Forest in a cash-and-stock deal valued at about $25 billion that is expected to close by the middle of the year.

Forest spokeswoman Mandy Kaufman said Monday that Actavis agreed to the Furiex acquisition bid and supports it.

For that deal, Forest plans to pay about $1.1 billion in cash, or $95 per share, for Morrisville, N.C.-based Furiex. It also will make additional payments of up to about $360 million depending on the development of eluxadoline, which treats the symptoms of a form of irritable bowel syndrome. Furiex announced initial results from late-stage testing on that drug in February and plans to submit it to regulators for approval by the end of this year's third quarter.

The treatment had received an FDA fast-track designation, which is designed to speed up the development and review of drugs that treat diseases with significant and unmet medical need.

Forest also plans to divest royalties Furiex receives on a couple of treatments to Royalty Pharma for about $415 million once the Furiex acquisition is completed. That would lower the price of the Furiex deal by about $315 million after taxes.

Earlier this year, Forest Laboratories Inc. also completed a $2.9 billion purchase of Aptalis, which makes gastrointestinal and cystic fibrosis treatments. Forest CEO Brent Saunders said Monday in a statement that the Furiex deal is a "natural extension" of his company's gastro-intestinal business following the Aptalis deal.

Forest has been hurt by generic competition to major drugs like the anxiety and depression treatment Lexapro. Saunders, the former CEO of optical products maker Bausch & Lomb Inc., took over last fall as Forest chief executive from the drugmaker's longtime leader Howard Solomon. Saunders had the backing of billionaire investor and Forest shareholder Carl Icahn.

Shares of Furiex jumped more than 28 percent, or $22.79, to $102.94 in Monday morning trading, while the Nasdaq exchange rose slightly. Forest shares, meanwhile, paralleled the broader market. They climbed 88 cents to $90.72.



Want unlimited access to seattletimes.com? Subscribe now!

News where, when and how you want it

Email Icon

The summer is wide open.

The summer is wide open.

Follow our three-part "Washington's National Parks" series running through August 10 for an in-depth look at some of our local treasures.

Advertising

Advertising


Advertising
The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►
The Seattle Times

To keep reading, you need a subscription upgrade.

We hope you have enjoyed your complimentary access. For unlimited seattletimes.com access, please upgrade your digital subscription.

Call customer service at 1.800.542.0820 for assistance with your upgrade or questions about your subscriber status.

The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Activate Subscriber Account ►